3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Glioblastoma
30
Carcinoma, Non-Small-Cell Lung
30
Lung Neoplasms
23
Head and Neck Neoplasms
21
Squamous Cell Carcinoma of Head and Neck
15
Lymphoma
15
Gliosarcoma
15
Central Nervous System Neoplasms
14
Sarcoma
12
Esophageal Neoplasms
12
Rectal Neoplasms
10
Glioma
10
Leukemia
9
Breast Neoplasms
9
Brain Neoplasms
9
Prostatic Neoplasms
8
Pancreatic Neoplasms
8
Lymphoma, Follicular
7
Esophageal Squamous Cell Carcinoma
7
Neoplasms
6
Melanoma
6
Leukemia, Lymphocytic, Chronic, B-Cell
6
Uterine Cervical Neoplasms
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Neoplasm Metastasis
5
Lymphoma, Large B-Cell, Diffuse
5
Lymphoma, B-Cell, Marginal Zone
5
Colorectal Neoplasms
5
Carcinoma, Renal Cell
5
Astrocytoma
5
Interventions
Imatinib Mesylate
4
ripretinib
2
pexidartinib
2
binimetinib
2
Sunitinib
2
tinostamustine
1
spartalizumab
1
pembrolizumab
1
avapritinib
1
Radiotherapy
1
Injections
1
HhAntag691
1
Gemcitabine
1
Everolimus
1
Drug Therapy
1
Blood Specimen Collection
1
Biopsy
1
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Gastrointestinal Stromal Tumors
×
Radiotherapy
×
Clear all
NCT00515931
2014-10-07
GIST-RT
University of Helsinki
Phase 1/2
Completed
25 enrolled